Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

BBG2Na vaccine

Known as: BBG2Na 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
We have addressed the safety of alum-adsorbed BBG2Na, a recombinant respiratory syncytial virus (RSV) subunit vaccine, in infant… Expand
Is this relevant?
2003
2003
Respiratory syncytial virus (RSV) is divided into subgroups A and B, based primarily on variation within the G glycoprotein. A… Expand
Is this relevant?
2003
2003
Prevention of respiratory syncytial virus (RSV) disease will implicate neonatal priming. However, neonatal antigen exposure… Expand
Is this relevant?
2002
2002
Human respiratory syncytial virus (hRSV) is one of the most common causes of respiratory infection in infants and the elderly… Expand
Is this relevant?
Highly Cited
2001
Highly Cited
2001
A novel recombinant respiratory syncytial virus (RSV) subunit vaccine, designated BBG2Na, was administered to 108 healthy adults… Expand
Is this relevant?
2001
2001
A BALB/c mouse model of enhanced pulmonary pathology following vaccination with formalin-inactivated alum-adsorbed respiratory… Expand
Is this relevant?
1999
1999
Alum-adsorbed BBG2Na, a recombinant vaccine derived in part from the respiratory syncytial virus (RSV) subgroup A G protein… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?
1999
1999
The relative immunopathogenic potential of a recombinant fusion protein incorporating residues 130-230 of respiratory syncytial… Expand
Is this relevant?
1997
1997
Maternal and neonatal immunization were evaluated for their capacity to induce protective immunity against respiratory syncytial… Expand
Is this relevant?
1997
1997
The polypeptide of aa 130-230 of the G protein (G2Na) of respiratory syncytial virus (RSV) was fused to BB, the albumin-binding… Expand
  • figure 1
  • figure 2
  • figure 4
  • figure 5
  • table 1
Is this relevant?